ACRS (STOCKS)
Aclaris Therapeutics, Inc.
$5.860000
+0.020000 (+0.34%)
Prev close: $5.840000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Neal S. Walker
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $909.39M
- Employees
- 64
- P/E (TTM)
- -9.98
- P/B (TTM)
- 6.55
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $8.22M |
| Benefits Costs and Expenses | $83.96M |
| Cost Of Revenue | $1.68M |
| Costs And Expenses | $94.53M |
| Gross Profit | $6.54M |
| Nonoperating Income/Loss | $10.58M |
| Operating Expenses | $92.85M |
| Research and Development | $63.34M |
| Other Operating Expenses | $29.51M |
| Operating Income/Loss | -$86.31M |
| Income/Loss From Continuing Operations After Tax | -$75.74M |
| Income/Loss From Continuing Operations Before Tax | -$78.47M |
| Net Income/Loss | -$75.74M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$75.74M |
| Net Income/Loss Available To Common Stockholders, Basic | -$75.74M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$0.58 |
| Diluted Earnings Per Share | -$0.58 |
| Basic Average Shares | 258,464,941 |
| Diluted Average Shares | 258,464,941 |
| Assets | $179.69M |
| Current Assets | $97.77M |
| Cash | $170.60M |
| Noncurrent Assets | $81.93M |
| Fixed Assets | $664.00K |
| Other Non-current Assets | $81.26M |
| Liabilities | $55.11M |
| Current Liabilities | $28.24M |
| Accounts Payable | $15.52M |
| Wages | $2.88M |
| Other Current Liabilities | $9.85M |
| Noncurrent Liabilities | $26.87M |
| Equity | $124.58M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $124.58M |
| Liabilities And Equity | $179.69M |
| Net Cash Flow From Operating Activities | -$62.06M |
| Net Cash Flow From Operating Activities, Continuing | -$62.06M |
| Net Cash Flow From Investing Activities | $3.53M |
| Net Cash Flow From Investing Activities, Continuing | $3.53M |
| Net Cash Flow From Financing Activities | $52.29M |
| Net Cash Flow From Financing Activities, Continuing | $52.29M |
| Net Cash Flow | -$6.24M |
| Net Cash Flow, Continuing | -$6.24M |
| Comprehensive Income/Loss | -$75.94M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$76.52M |
| Other Comprehensive Income/Loss | -$786.00K |